The following is a summary of “Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization ...

Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

Spesolimab demonstrated rapid and substantial efficacy in treating generalized pustular psoriasis (GPP), particularly in reducing pustulation, with a favorable safety profile, according to results of ...